Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 52-Week Low - Time to Sell?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) shares hit a new 52-week low during trading on Wednesday . The stock traded as low as $26.88 and last traded at $27.34, with a volume of 34005 shares changing hands. The stock had previously closed at $27.33.

Analyst Ratings Changes

Several analysts have commented on AMPH shares. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price objective on the stock. Piper Sandler lowered Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $66.00 to $36.00 in a report on Tuesday, February 4th.

Amphastar Pharmaceuticals Trading Up 1.6 %

The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of 8.89, a PEG ratio of 2.19 and a beta of 0.77. The company has a fifty day moving average price of $32.73 and a two-hundred day moving average price of $41.19.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company's stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 27.10% of the stock is owned by company insiders.

Remove Ads

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its position in Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after purchasing an additional 493 shares during the period. Parkside Financial Bank & Trust grew its stake in shares of Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after buying an additional 871 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at $38,000. Point72 Asia Singapore Pte. Ltd. lifted its stake in Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock worth $56,000 after acquiring an additional 398 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after acquiring an additional 348 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.